1. Introduction {#s0005}
===============

Traumatic brain injury (TBI) accounts for over 90% of the brain injuries in USA, and is common in sport related injuries, military, and domestic environments. TBI is characterized by a high level of complexity based on the multiple components involved in the onset and progression of the pathology. TBI compromises neuronal function and cognitive abilities that can last for years after the first incident ([@bb0120], [@bb0115], [@bb0200]). Mild TBI such as concussive injury is particularly difficult to diagnose since several of its symptoms such as blurred vision, headache, nausea, dizziness could be caused by other reasons ([@bb0115], [@bb0200]), though about 20% of patients develop persistent symptoms that can last for years. Neurons that survive the initial insult show a decline in function ([@bb0315], [@bb0020]), but the underlying regulatory mechanisms have proven difficult to grasp based on information derived from isolated molecular events. The lack of comprehensive mechanistic information has left unanswered one of the most intriguing aspects of TBI, which is why many patients become vulnerable to other neurological disorders such as chronic traumatic encephalopathy (CTE), Alzheimer\'s disease (AD), and posttraumatic stress disorder (PTSD) ([@bb0115], [@bb0200]). The complexity of the TBI pathology becomes even a larger limiting factor for the design of strategies to diagnose and to predict the outcome of concussive injury ([@bb0040], [@bb0095]).

To address these knowledge gaps in the pathogenesis of TBI, we conducted a comprehensive systems biology study ([Fig. 1](#f0005){ref-type="fig"}) focusing on the impact of concussive injury on fundamental gene regulatory mechanisms. Unlike previous studies based on microarrays ([@bb0290], [@bb0215], [@bb0220], [@bb0205]) and more recently RNA sequencing ([@bb0125]) which have reported changes in gene expression in response to TBI, in the current study we leveraged the power of system biology to combine genome-wide transcriptome and DNA methylome analyses in the hippocampus (a main site of cognitive dysfunction in TBI pathology) with modern data-driven gene network modeling approaches, which allowed us to extract information about crucial gene regulatory mechanisms (expression level, alternative splicing, epigenetic regulation) underlying TBI pathogenesis and to model tissue-specific gene-gene interactions which have the power to predict essential regulatory points. Gene networks are graphical models that depict genes as nodes and connections (reflecting regulatory relations or interactions) between genes as edges. Networks can be used to identify key driver genes that connect a large number of genes in a network affected by TBI, and are likely potent therapeutic targets ([@bb0140], [@bb0165], [@bb0225], [@bb0300], [@bb0350]). To infer translatability to human pathophysiology, we analyzed the intersection of the molecular signals from our TBI rodent model with human genome-wide association studies (GWAS) of brain disorders.Fig. 1**Overall genomic study design.** We assessed transcriptomic and epigenomic profiling of hippocampus and blood leukocytes, followed by network modeling and key driver identification. Transcriptomic and epigenomic profiling of blood samples was compared to that of hippocampus to identify genomic features in concordance with the brain signals for biomarker identification. We characterized the functional relevance of the brain genomic signatures and networks to TBI characteristics and behavior outcomes (learning and memory). By intersecting with human genome-wide association studies (GWAS), many TBI signature genes and network regulators identified in the rodent model were found to be causally associated with brain disorders with relevant link to TBI.Fig. 1

We also took advantage of our system biology paradigm to uncover a possible association between genomic changes in brain and periphery driven by TBI, which could shed light on the possible implementation of blood genomic biomarkers of TBI pathology in the brain. The current standard for biomarker research focuses on individual protein products in the cerebrospinal fluid or blood plasma ([@bb0335], [@bb0340]) that are by-products of TBI pathology and do not capture central regulatory mechanisms driving pathogenesis. Protein biomarkers also impose technical challenges due to limitations in the sensitivity of bioassays ([@bb0335], [@bb0340]). Additionally, blood leukocytes are abundant in the circulation and have been lately found to serve as a source of surrogate markers for AD ([@bb0210]) and Parkinson\'s disease (PD) ([@bb0150]). Comparison of the genomic signals between hippocampus and blood leukocytes facilitates the extraction of blood genomic markers that can trace the hidden aspects of the brain pathology of TBI.

2. Materials and methods {#s0010}
========================

2.1. Fluid percussion injury (FPI) as a rodent model of concussive injury {#s0015}
-------------------------------------------------------------------------

Adult male Sprague--Dawley rats (Charles River Laboratories, Inc., MA, USA) weighing 200--220 g were maintained under standard housing conditions (room temperature 22--24 °C) with 12 h light/dark cycle ([@bb0005]). The rats were kept individually in polyacrylic cages with free access to food and water. After acclimatization for one week on standard rat chow, rats were randomly assigned to sham control (n = 10) and FPI (n = 10) groups. FPI was performed by making a 3-mm diameter craniotomy with a trephine centered on the sagittal suture between bregma and lambda. A Teflon disk (1 mm) was placed over the craniotomy, and the cap was filled with 0.9% saline solution. At the first sign of hind-limb withdrawal to a paw pinch, a moderate fluid percussion pulse (approx. 1.8--2.3 atm) was administered using a FPI device (Virginia Commonwealth University). Apnea and unconsciousness times were determined. Sham animals underwent an identical preparation with the exception of FPI. All experiments were performed in accordance with the United States National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the University of California at Los Angeles (UCLA) Chancellor\'s Animal Research Committee (ARC). Rats were sacrificed at two post-injury time points and samples from both 24 h and 7 d were used for molecular analysis. The acute period of TBI (24 h) is crucial for biomarker discovery ([@bb0095], [@bb0335]), and was used to predict the pathology that is further developed by the sub-acute period (7 d) including inflammation, degeneration, and early regeneration. In addition, we used the gene profile from 7 d to assess the overlap between signature genes and candidate genes of brain disorders since at this stage the pathology is underway.

2.2. Barnes maze test {#s0020}
---------------------

Rats were tested with the Barnes maze test before and after TBI. Animals were trained to locate a dark escape chamber, hidden underneath a hole positioned around the perimeter of a disk, brightly illuminated by four overhead halogen lamps to provide a low level aversive stimulus. Animals were trained before TBI with two trials per day for five consecutive days. A trail started by placing the animal in the center of the maze covered under a cylindrical start chamber; after a 10-s delay, the start chamber was raised. A training session ended after the animal has entered the escape chamber or when a pre-determined time (5 min) has elapsed. In order to assess memory retention, two trials were given on day 7 post-TBI. We recorded and quantified behavior using AnyMaze video tracking software (San Diego Instruments).

2.3. Tissue collection {#s0025}
----------------------

Right after the last memory test, rats were sacrificed by decapitation and hippocampus were dissected out, frozen on dry ice, and stored at − 70 °C for later use. Blood samples were collected retro-orbitally under isoflurane anesthesia into EDTA-coated Vacutainers (BD Diagnostics, Franklin Lakes, New Jersey) 24-h post FPI, and immediately centrifuged at 1600*g* for 10 min at 4 °C. The buffy coat layer containing leukocytes and platelets was carefully transferred to a new tube without disturbing the underneath leukocytes, and washed twice with 15 ml of EL Buffer (QIAGEN GmbH, Hilden, Germany) for 15 min at 4 °C. Total cellular DNA and RNA were extracted using the AllPrep DNA/RNA mini kit (QIAGEN GmbH, Hilden, Germany).

2.4. RNA sequencing (RNA-Seq) and data analyses {#s0030}
-----------------------------------------------

RNA samples from hippocampus and leukocytes (n = 5 per treatment group per tissue) were used for RNA-Seq to assess alterations in the transcriptome. RNA was first processed via poly-A selection and fragmentation, reverse transcribed into cDNA, and sequencing adapters ligated using the Illumina Paired-End sample prep kit. Fragments of 250-400 bp were isolated, amplified, and sequenced on an Illumina Hiseq2500 System. Paired-end RNA-Seq reads were mapped using TopHat2/Bowtie2 ([@bb0105]). Differentially expressed genes, transcripts, and alternative splicing events were further identified using Cufflinks and Cuffdiff ([@bb0270], [@bb0275]). A statistical cutoff of p \< 0.01 was used to define TBI gene signatures. Multiple testing was corrected using false discovery rate (FDR) estimated with the Benjamini-Hochberg (BH) method ([@bb0015]). The RNA-Seq data was deposited to Gene Expression Ominbus (GEO) with accession number GSE64978 (hippocampus) and GSE68207 (leukocytes).

2.5. Quantitative real-time PCR (qPCR) to confirm top transcriptome signals {#s0035}
---------------------------------------------------------------------------

We chose to validate 7 differentially expressed genes (*F5*, *Lgmn*, *Pls1*, *Cd63*, *Cdr2*, *Gch1*, *Vwf*) that were common between hippocampus and leukocytes using qPCR. First-strand complementary DNA was synthesized using the iScript cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, California) and 100 ng total RNA according to the manufacturer\'s instructions. qPCR was carried out using the SsoFast EvaGreen Supermix kit (Bio-Rad Laboratories, Hercules, California) to amplify the candidate genes in the CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, California), with Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) as an endogenous control. Each experiment was repeated twice independently.

2.6. Functional annotation of genes altered by TBI {#s0040}
--------------------------------------------------

Signature genes identified from RNA-Seq analyses were classified for their biological functions using Molecular Signatures Database (MSigDB, <http://www.broadinstitute.org/gsea/msigdb/index.jsp)> ([@bb0250]), which catalogs canonical pathways or functional categories from various databases including Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/pathway.html>), BioCarta (<http://www.biocarta.com/genes/index.asp>), Reactome (<http://www.reactome.org/>), and gene sets derived from Gene Ontology (GO, <http://www.geneontology.org/>). Fisher\'s exact test was performed to calculate the enrichment p-values for each pathway or functional category within each gene signature. Results were corrected for multiple comparisons of hundreds of pathways using Bonferroni correction and Bonferroni-corrected p \< 0.05 was considered significant.

2.7. Relationship between gene expression and behavior phenotypes {#s0045}
-----------------------------------------------------------------

Gene expression levels of the signature genes identified from RNA-Seq analysis were tested for the association with behavior traits (latency time in the Barnes Maze test) by Pearson correlation. p value \< 0.05 was considered significant.

2.8. Reduced representation bisulfite sequencing (RRBS) {#s0050}
-------------------------------------------------------

RRBS libraries were constructed from the DNA samples of hippocampus and leukocytes (n = 5 per treatment group per tissue) ([@bb0160]) by digesting 1 μg of genomic DNA with *MspI*. Digested DNA was then purified, end-repaired, and adenylated, followed by ligation to Illumina TruSeq barcode adapters. Fragments of size 150--300 bp were selected, bisulfite-treated, and sequenced using an Illumina Hiseq 2500 System. Sequences were called using standard Illumina software and bisulfite-converted reads were aligned to the genome using BS Seeker ([@bb0030]). Methylation percentages at each cytosine were computed and compared between treatment groups using methylKit, an R package implanted with logistic regression test, and the sliding linear model (SLIM) ([@bb0295]) to adjust p-values to q-values to correct for multiple testing. Loci with methylation level differing by \> 25% between groups and q \< 0.05 were considered significant, and defined as differentially methylated loci (DMLs). Differential genes from RNA-Seq and local DMLs within 10 kb distance were compared for overlap and correlated using Pearson correlation. RRBS data was deposited to GEO with accession numbers [GSE64984](ncbi-geo:GSE64984){#ir0030} (hippocampus) and GSE79270 and GSE83776 (leukocytes).

2.9. Assessing overlap between TBI signatures and candidate genes of brain disorders from human GWAS {#s0055}
----------------------------------------------------------------------------------------------------

We tested the consistency between the genes affected by TBI from our study and those from human GWAS related to brain functions in two ways. First, we cross-checked genes identified in our study with top GWAS candidate genes reported in the GWAS catalog ([@bb0070]) (<http://www.ebi.ac.uk/gwas/>) for direct overlap. Second, we used a SNP Set Enrichment Analysis (SSEA) ([@bb0140]), which goes beyond the top GWAS hits and tests the overall enrichment of the genes affected in our TBI animal model for SNPs that demonstrated disease association in human GWAS using Kolmogorov-Smirnov (KS) test and Fisher\'s exact test. Bonferroni-corrected p \< 0.05 by either KS test or Fisher\'s exact test was considered significant.

2.10. Network models of TBI genomic signatures {#s0060}
----------------------------------------------

We constructed tissue-specific Bayesian gene networks (BN) maps based on global gene expression patterns to reflect gene-gene relationship and organization. BNs are graphical models that depict genes as nodes and connections between genes as edges defined based on global genomic data. Network connections among genes in BNs have been shown to accurately capture the functional and mechanistic relationship of genes that can inform on disease mechanisms and help define composite sets of molecular markers ([@bb0035], [@bb0140], [@bb0165], [@bb0300], [@bb0320], [@bb0325], [@bb0350], [@bb0365]). BNs for brain and blood were constructed based on genetic and transcriptomic data from several large-scale human and mouse studies ([@bb0285], [@bb0300], [@bb0170], [@bb0045], [@bb0055]) each involving hundreds of individuals, using a previously established method by Zhu et al. ([@bb0365], [@bb0360]). These studies are all population-based and reflect broad spectrums of physiological states and, therefore, can capture intrinsic gene-gene interactions across conditions. The large sample sizes involved in these studies also ensure the statistical power to infer accurate networks from each study. The edges in the BNs are defined by conditional probabilities that characterize the distribution of states of each gene given the state of its parents ([@bb0190]). The network topology defines a partitioned joint probability distribution over all genes in a network. The likelihood of a BN network model given observed transcriptomic data was determined using the Bayes formula. For each dataset, 1000 Bayesian networks, each using different random seeds, were reconstructed using Monte Carlo Markov Chain simulation ([@bb0135]). Bayesian Information Criteria was used to determine the model with the best fit for each network. From the resulting set of 1000 networks, edges that appeared in \> 30% of the networks were used to define a consensus network. To infer causal directions between genes in a network, genetic information was used as priors ([@bb0355]). For each tissue, the union of nodes and edges from BNs of multiple studies was used as the tissue-specific network, and the predictive power of multi-study union networks has been supported previously ([@bb0140], [@bb0165], [@bb0300]). To derive gene subnetworks affected by TBI, we used the signature genes identified from the RNA-Seq analysis as seeds to extract the top most connected subnetworks within the BNs as described previously ([@bb0320]). Network visualization was carried out using Cytoscape ([@bb0240]).

2.11. Identification of key drivers (KD) of TBI signatures {#s0065}
----------------------------------------------------------

A previously established Key Driver Analysis (KDA) was used to identify the potential key regulators, or key drivers (KDs) for the TBI signature genes based on the topology of BN network models ([@bb0300], [@bb0325]). Conceptually, KDA aims to identify genes whose network neighbors are more likely to be genes affected by TBI than expected by random chance. Because these genes act as "hubs" that are surrounded by TBI genes, it is more likely that they regulate the activities of genes affected by TBI. Statistically, KDA takes as input a set of genes G (i.e., genes affected by TBI in each tissue) and a gene network N (BNs described above). For every gene N~k~ in the network N, the neighboring genes of N~k~ within 3-edge distance were tested for enrichment of genes in G using Fisher\'s exact test. Network genes that reach Bonferroni-adjusted p \< 0.05 were reported as KDs.

3. Results {#s0070}
==========

3.1. TBI promotes large-scale alterations in the transcriptional activities of genes {#s0075}
------------------------------------------------------------------------------------

We conducted RNA-Seq analysis of hippocampus and leukocyte samples from rats exposed to TBI (n = 5) or sham surgery (n = 5). At p \< 0.01, we identified 240 and 1052 differentially expressed genes, 111 and 739 differentially expressed transcripts, and 23 and 93 genes showing alternative exon usage in hippocampus and leukocytes, respectively (Table S1 in Dataset S1). We pooled all these genes to define 268 (121 pass false discovery rate or FDR \< 10%) and 1215 (1092 pass FDR \< 10%) unique genes as gene "signatures" for hippocampus and leukocytes, respectively, and used these signatures for downstream integrative analysis. As illustrated in [Fig. 2](#f0010){ref-type="fig"}a, a majority of the hippocampal signatures had increased expression, whereas the opposite is true for leukocyte, suggesting directional differences in the transcriptional response to TBI between the brain and the peripheral. Between the two tissues, 18 common genes were identified ([Fig. 2](#f0010){ref-type="fig"}b), including *Abca4*, *Adipor1*, *Aqp1*, *Asap1*, *Cd63*, *Cdr2*, *Dennd2c*, *F5*, *Fam46a*, *Gch1*, *Gulp1*, *Laptm4b*, *Lgals3bp*, *Lgmn*, *Lrg1*, *Oasl*, *Pls1*, *Vwf*. When only considering the gene-level changes, there were 16 shared genes, with 13 (*Abca4*, *Adipor1*, *Aqp1*, *Cd63*, *Cdr2*, *Dennd2c*, *Gch1*, *Gulp1*, *Laptm4b*, *Lgals3bp*, *Lgmn*, *Oasl*, *Pls1*) showing opposite expression changes and three (*Asap1*, *Lrg1*, *Vwf*) showing the same direction in both tissues. Additionally, we tested the reliability of the differential signals using qPCR experiments on 7 shared genes (*F5*, *Lgmn*, *Pls1*, *Cd63*, *Cdr2*, *Gch1*, *Vwf*) between hippocampus and leukocytes, and confirmed the differential expression patterns observed in RNA-Seq in both tissues (Table S2 in Dataset S1).Fig. 2Impact of TBI on transcriptome and DNA methylome in hippocampus and leukocytes. A) Heatmaps of differentially expressed genes in both tissues. Blue to red colors indicate low to high expression values. B) Overlap of differential transcriptomic signatures between tissues, and enrichment p value according to Fisher\'s exact test. C) Overlap of over-represented molecular pathways in the signatures genes between tissues, and enrichment p value according to Fisher\'s exact test. D) Top shared pathways between tissues. Bars are the fold enrichment of pathways and the values next to the bars are the Bonferroni-corrected enrichment p values according to Fisher\'s exact test. E) Heatmap of differential methylation loci (DML) in both tissues. Blue to red colors indicate low to high expression values. F) Overlap of DML between tissues, and enrichment p value according to Fisher\'s exact test.Fig. 2

Among all the hippocampal signatures, there were 28 unique genes showing expression differences at the levels of transcripts or exons but not at gene level, indicative of the importance of TBI-induced alternative splicing in these genes. Similarly, leukocyte signatures also contained 163 unique genes with altered transcriptional activity only at the transcript and exon levels, supporting even broader impact of TBI on the gene alternative splicing events in blood cells. Additionally, many of the signature genes are known splicing regulators, including the hippocampal signature *Rbm47* and the leukocyte signatures *Bcas2*, *Clasrp*, *Lsm6*, *Luc7l3*, *Prpf4b*, *Qk*, *Rbm25*, *Rbm38*, *Rbpms2*, *Sfrs18*, *Snrnp40*, and *Uhmk1.*

Increasing evidence indicates that alternative splicing is an inherent mechanism in the etiology of various diseases. Accordingly, TBI affected alternative splicing of genes involved in diverse functions related to neurons (*Neurod1*, *Neurod4*, *P2ry4*, *P2ry1*, *Htr2c*, *Npy*, *Agrp*), complement and coagulation *(C3*, *F5*, *Vwf*), transcriptions factors *(Aff3*, *Zbtb16)*, blood pressure *(Sgk1*, *Ace*, *Angpt1*, *Gucy1a3*, *Gucy1b3*), inflammation (*Tlr7*, *Ccl9*, *Cxcl2*, *Ccr1*, *Alox15*, *Alox12*), mitochondria (*Atp13a4*, *Atp61f*, *Atp6v0d1*, *Cox6a1*, *Cox8a*, *Cox20*, *Ndufa8*, *Ndufa11*, *Ndufa12*), leptin signaling (*Npy*, *Agrp*), insulin signaling (*Irs1*), and extracellular matrix (ECM) genes (*Spp1*, *Mmp2*, *Bgn*). The alternatively spliced genes *F5* and *Zbtb16* have been associated with hippocampal atrophy and conduct behavior, respectively in human GWAS.

3.2. Correlation between hippocampal transcriptome signatures of TBI and behavior phenotypes {#s0080}
--------------------------------------------------------------------------------------------

As hippocampus is important for cognitive function, we tested the hippocampal gene expression changes with the effects of TBI on memory. Among the 240 hippocampal signatures with changes at the gene level, 5 (*Cldn4*, *Cldn5*, *Klhdc8a*, *Lrg1*, and *Lrrc10b*) showed significant correlation with the latency time detected in the Barnes maze (p \< 0.05; [Fig. 3](#f0015){ref-type="fig"}).Fig. 3Correlation between TBI hippocampal signature genes and latency time in memory test. Gene expression level is represented by fragments per kilobase of transcript per million RNA-Seq mapped reads (fpkm) on the x-axis and the Barnes maze latency time measured in the matched animals is shown on the y-axis. Correlation strength is indicated by the correlation coefficient R and the p value.Fig. 3

3.3. Functional categorization of hippocampal and leukocyte transcriptomic signatures {#s0085}
-------------------------------------------------------------------------------------

We annotated the signature genes based on known pathways or functional categories curated in KEGG, BioCarta, and Reactome, and found enrichment of both tissue-specific and shared biological pathways between hippocampus and leukocytes (Table S3 in Dataset S1). At Bonferroni-corrected p \< 0.05, we found 132 and 553 over-represented pathways for hippocampal and leukocyte signatures, respectively, among which 97 were in common when only considering exact matches in pathway names ([Fig. 2](#f0010){ref-type="fig"}c). When highly overlapping pathways with non-identical names were considered, the converging pathways between tissues are even greater, with majority of the hippocampal pathways captured in the leukocyte pathways. The shared pathways included axon guidance, neurotransmission, ECM, focal adhesion, lysosome, transmembrane transport of small molecules, hemostasis, platelet activation signaling and aggregation, immune system, vascular smooth muscle contraction, class *A*1 rhodopsin-like receptors, and various signaling pathways for insulin, glucagon, IGF, FGFR, NGF, neurotrophin, PDGF, and TLR (representative shared pathways are illustrated in [Fig. 2](#f0010){ref-type="fig"}d). These results indicate that despite the small overlap in individual signature genes and the largely opposite expression patterns between hippocampus and leukocytes, at pathway level there is substantial overlap.

The main hippocampal-specific pathways included olfactory transduction and growth hormone receptor signaling. In contrast, a larger number of pathways are leukocyte-specific, including cell cycle, oxidative phosphorylation, interferon signaling, cardiomyopathy, PPAR alpha, metabolic pathways for glucose, lipid and lipoproteins, fatty acids and triglycerides, and signaling pathways for NCAM, Notch, TGF-beta, WNT, PARKIN, mTOR, VEGF, and disease related gene sets for AD, PD, depression, and Huntington\'s disease.

3.4. TBI induced large-scale DNA methylomic changes in hippocampus and leukocytes {#s0090}
---------------------------------------------------------------------------------

To identify epigenomic changes associated with TBI, we examined the DNA methylome using reduced representation bisulfite sequencing (RRBS) that measures millions of potential DNA methylation sites at single base resolution. We found that TBI induced a large-scale switch of the methylation patterns in both tissues: at FDR \< 5%, 781 and 758 of differentially methylated loci (DMLs) showed hypomethylation and hypermethylation in hippocampus, respectively. In leukocytes, we identified 915 and 892 DMLs with hypomethylation and hypermethylation, respectively ([Fig. 2](#f0010){ref-type="fig"}e). Between the two tissues, there are 269 shared methylation sites, which represent statistically significant overlap ([Fig. 2](#f0010){ref-type="fig"}f).

3.5. Relationship between differential methylation and differential expression {#s0095}
------------------------------------------------------------------------------

To explore the potential relationship between DMLs and gene expression, we mapped the TBI DMLs in each tissue to adjacent genes within 10 kb distance. We found in both hippocampus and leukocytes, \~ 50%, \~ 30%, and 16% of DMLs were located in the intergenic regions, gene body (including 5′-UTR, intron, coding sequence, and 3′-UTR), and the upstream or downstream regions of the genes, respectively (Table S4 in Dataset S1). Assessing the methylome-transcriptome relationship revealed certain co-clustering of DMLs and gene signatures ([Fig. S1](#ec0010){ref-type="supplementary-material"}). For instance, 13 out of the 268 (4.8%) hippocampal signature genes and 65 out of the 1215 (5.3%) leukocyte signature genes co-localized with DMLs within 10 kb distance; 7 hippocampal and 24 leukocyte signature genes were significantly correlated with their local DMLs at p \< 0.05 based on Pearson correlation analysis. For example, gene *Atp6v0d1* showed a significant positive correlation with its local DML (correlation coefficient r = 0.90, p = 2.18E-3), and gene *Igf1r* had a significant negative correlation with its local DML (r = − 0.86, p = 6.54E-3) in leukocytes. Additionally, 32 out of the 268 (11.9%) hippocampal signature genes and 130 out of the 1215 (10.7%) leukocyte signature genes co-localized with DMLs within 50 kb distance (Table S5 in Dataset S1), suggesting *cis*-regulation of gene expression by the local DMLs. Notably, some of the genes containing local DMLs are transcription factors, including *Irx6* and *Zbtb16* from hippocampus and *Dpf3*, *Foxo3*, and *Zfp219* from leukocytes, or epigenetic factors such as *Gadd45g*, *Morf4l1*, and *Rgs1* from leukocytes, which could in turn *trans*-regulate downstream target genes.

3.6. Identification of key drivers and gene subnetworks mediating the effects of mTBI in hippocampus and leukocytes {#s0100}
-------------------------------------------------------------------------------------------------------------------

To explore the gene-gene relations among the hippocampus or leukocyte signature genes and to identify potential key perturbation points of TBI that triggered the transcriptomic changes, we employed multiple data-driven Bayesian networks (BNs) ([@bb0355], [@bb0365]) that elucidate gene-gene regulatory relationships based on brain and blood genomic data of several large independent human and rodent populations (detailed in [Materials and methods](#s0010){ref-type="sec"}). Using these networks and a network topology-based key driver analysis (KDA), we identified candidate key driver (KD) genes whose network neighboring genes highly overlapped with the signature genes for hippocampus and leukocytes, among which 127 KDs were common to both tissues (Table S6 in Dataset S1). As illustrated in [Fig. 4](#f0020){ref-type="fig"}a, a subnetwork containing two shared KDs, *Anxa2* and *Ogn*, was highly enriched with both hippocampal and leukocyte signatures, although the signature genes themselves did not overlap. Other notable shared KDs between tissues include ECM genes such as *Fmod*, *Dcn*, *Pcolce*, *Col1a1*, *Col3a1*, and *Col23a1* and transcription factors *Tcf7l2* and *Cebpd*. Some of these KDs also form a subnetwork ([Fig. 4](#f0020){ref-type="fig"}b). Both subnetworks coordinate genes primarily functioning in ECM-receptor interaction, complement and coagulation cascades, and focal adhesion. The network-level co-localization of TBI signature genes between the two tissues agrees with the pathway-level overlap observed above, and suggests that TBI affects similar functional processes in both tissues through shared regulatory mechanisms.Fig. 4Shared subnetworks between hippocampal and leukocyte signature genes. A) A subnetwork centered at shared key drivers (KDs) *Anax2* and *Ogn*. B) A subnetwork centered at shared KDs *Fmod*, collagen genes, and *Cebpd*. Larger red nodes are the KDs; blue and yellow nodes denote hippocampal and leukocyte signature genes, respectively. Grey nodes are network genes in the neighborhood of KDs that are not affected by TBI.Fig. 4

3.7. Relevance of hippocampal and leukocyte signatures and KDs to human diseases {#s0105}
--------------------------------------------------------------------------------

TBI has been associated with a number of brain disorders. To assess the relevance of our signals from the rodent TBI model to human pathophysiology, we compared the hippocampal and leukocyte signature genes as well as the KDs to human GWAS of brain related diseases or traits. Human GWAS genes of brain disorders most likely play causal roles in disease development, because genetic variations that drive changes in genes or gene products are inherited at birth and precede disease manifestation. If TBI affects these disease genes uncovered in human genetic studies, it is likely that TBI will also impose predisposition to brain disorders. When directly comparing with top candidate genes curated in the GWAS catalog, we found numerous overlapping genes between TBI signature or KD genes and top GWAS hits for a broad range of brain disorders including AD, attention deficient hyperactive disorder, autism, depression, addiction, PTSD, schizophrenia, and PD (representative overlapping genes in hippocampus shown in [Table 1](#t0005){ref-type="table"}; full lists for both tissues in Table S7 in Dataset S1). When using a SNP set enrichment analysis (SSEA) that utilized full sets of GWAS results we had accessed for AD ([@bb0065], [@bb0100], [@bb0180]), cognitive traits ([@bb0235]), psychiatric disorders ([@bb0195]), and smoking behavior [@bb0265]), we found that human orthologs of the TBI signature genes and KDs derived from both hippocampus and leukocytes were significantly enriched for genetic polymorphisms associated with many of these diseases or traits (Table S8 in Dataset S1).Table 1Overlapping genes between TBI hippocampal signatures or KDs and human GWAS genes of brain disorders. Human GWAS candidate genes were derived from the GWAS catalog (p \< 1e-5).Table 1GWAS diseaseOverlapping gene in TBI hippocampal signatureAlcohol consumption/dependence*CUX2*; *SLC26A4*; *ZDHHC21*; *ESR1*; *SERINC2*AD*APOE*; *NMU*; *PCDH11X*; *PPP1R3B*; *PROX1*; *SCARA3*; *SMC2*; *TTLL7*; *ADAMTS9*; *ARHGAP20*; *CAMK4*; *ELMO1*; *LIPC*; *PDE7B*; *PLEKHG1*; *SP6*ADHD*BCL11A*; *CDH13*; *LRRC7*; *LYPLAL1*; *NR4A2*; *SEMA3A*; *TCEB1*; *TGFB2*; *TSHZ2*; *ZIC5*; *PAWR*; *NDN*, *ESRRB*; *ADAMTS2*; *LRRN3*; *TYRP1*Bipolar disorder*ANK3*; *COLEC12*; *DGKH*; *DPP10*; *IRF2BP2*; *ITIH3*; *MRPS23*; *MSI2*; *NFIA*; *PDE10A*; *PGM5*; *PPM1M*; *SIAE*; *SP8*; *TTC39B*; *UACA*; *CGNL1*; *DMTF1*; *FAT4*Bipolar disorder and schizophrenia*ARC*; *ATP6V1B2*; *BAI1*; *CACNA2D1*; *CMYA5*; *COMMD10*; *CST7*; *CTNND2*; *DDX52*; *DMD*; *HACE1*; *IRX1*; *KAT2B*; *MRVI1*; *MYO1E*; *PRKCQ*; *PTPRN2*; *SIM1*; *SLC39A12*; *TMEM212*; *TTC39B*; *VPS13C*Brain connectivity*CNTN4*; *EPHA7*; *NEDD4*Brain structure*BOK*; *CADPS2*; *GRIN2B*Cognitive function*PTPRO*; *AFAP1L2*; *CDH13*; *FAT4*; *GABRQ*; *GRIN2B*; *HCCS*; *IMMP2L*; *IRX1*; *IRX2*; *JUN*; *KIAA1217*; *KLHL1*; *LHX2*; *LIPC*; *MCTP2*; *NR2F2*; *PLCB1*; *RIT2*; *TOX*; *TSHZ3*; *UNC13C*; *VANGL2*; *ZNF788*; *LMO4*Word reading*NOS1AP*; *TACSTD2*; *TYRP1*Working memory*CLDN1*; *DRD2*; *LPHN3*Conduct disorder*C1QTNF7*; *MCTP2*; *NR2F2*; *RIT2*; *ST8SIA4*; *ZBTB16*; *KCNA5*; *PDE10A*Eating disorders*CAMK1D*; *DLGAP1*Hippocampal atrophy/volume*APOE*; *COL18A1*; *F5*; *MAGI2*; *MAL2*; *DPP4*; *MSRB3*Intelligence*CNTN4*; *COL1A2*; *GYPC*; *KIF16B*Major depressive disorder*ADCYAP1R1*; *CCND2*; *CDH9*; *EMP1*; *GRIN2B*; *HAPLN1*; *HOMER1*; *IGFBP3*; *KCNH5*; *NDFIP2*; *NEUROD6*; *PCLO*; *RASGEF1B*; *ATP6V1B2*Parkinson\'s disease*BMP4*; *DLG2*; *GPRIN3*; *RIT2*; *RORA*; *SEMA5A*; *STK39*; *VPS13C*; *WNT3*PTSD*COBL*; *PCSK2*; *PRKCA*; *SLC4A5*Schizophrenia*ANK3*; *BMP7*; *CDH13*; *CXCL12*; *GNAL*; *NRGN*; *PCDH20*; *PDC*; *PTGS2*; *RORA*; *SNX7*; *TCF4*; *VPS13C*Smoking behavior*BDNF*; *CHRNA3*; *CHRNA5*; *KCND2*; *MAOB*; *PDE1C*

4. Discussion {#s0110}
=============

We utilize systems biology strategies that have yielded breakthroughs in our understanding of mechanisms of complex disorders in recent years ([@bb0035], [@bb0075], [@bb0140], [@bb0165], [@bb0185], [@bb0230], [@bb0300], [@bb0320], [@bb0325], [@bb0350]) to determine the impact of TBI on fundamental gene regulatory mechanisms and biological pathways underlying pathogenesis. The majority of the genetic causal risks of complex human diseases such as Alzheimer\'s disease involve alterations of key pathogenic pathways ([@bb0100], [@bb0145]). We found that transcriptomic signatures in hippocampus and in leukocytes converge on functional categories of genes modulating important cellular functions such as inflammation, metabolism, and cell communication. The gene regulatory mechanisms uncovered from the current study span from epigenetic regulation and alternative splicing to gene network regulation. Alterations of these regulatory mechanisms studied in our rodent model of TBI could explain how the incidence of TBI alters the course of brain homeostasis and increases the risk of related brain pathologies in humans. This possibility was verified by integrating the results of rodent gene signatures with human GWAS, which catalog putative causal elements in human diseases. We found that key signature genes and their regulators affected by TBI in rodents have been associated with brain disorders with known association to TBI. The overall results of our system biology study provide evidence for the impact of TBI on core aspects of gene regulation, which offers critical mechanistic information at the molecular level and can be used as novel elements of diagnosis and treatment. Compared to previous genomic profiling studies of TBI ([@bb0290], [@bb0215], [@bb0220], [@bb0205], [@bb0125]), our study differs in the molecular features assessed (gene expression only in previous studies vs. the combination of epigenome, gene expression, and alternative splicing in the current study), network modeling approaches (literature-based networks in previous studies vs data-driven, tissue-specific networks used here), tissues, time points, and TBI severity, which offer unique mechanistic aspects of the TBI pathology.

DNA methylation is a major epigenetic mechanism responsible for changing the program of genes thus deviating towards disease states ([@bb0110], [@bb0260]). An increasing body of evidence indicates that predisposition to various neurological and psychiatric disorders are saved as epigenetic modifications ([@bb0080], [@bb0280]), and blast exposure results in changes in neuronal DNA methylation ([@bb0060]). Our results showing the impact of TBI on DNA methylation of multiple genes in both hippocampus and leukocytes provide the opportunity to examine how the effects of TBI can be saved with the potential to regulate gene transcription. Indeed, the action of TBI on the epigenome was revealed on select DNA methylomic alterations that co-localized and correlated with transcriptomic signature genes. It should be noted that correlation is not equal to causality and further validation experiments are warranted to investigate the causal relationship between the epigenome and the transcriptome. Alternative splicing is emerging as another gene regulatory mechanism by which the genome influences the etiology of various diseases such as AD ([@bb0310]). Our results show that TBI affects numerous alternatively spliced genes in the hippocampus and leukocytes involved in functions such as coagulation, blood pressure, inflammation, energy management, and ECM regulation. Further examination of these genes could guide the identification of particularly vulnerable points and mechanisms through which the TBI pathology could deviate to other disorders. For example, many of the signature genes are known splicing regulators such as *Rbm47*, *Sfrs18*, *Snrnp40*, and *Uhmk1.* Among these, *Uhmk1* has been recently related to genetic disposition to cerebral visual impairment ([@bb0025]) while *Rbm47* confers genetic risk to high blood pressure and cardiovascular disease ([@bb0255]), and both traits are common aspects of TBI pathology. Our results portray both epigenomic modification and alternative splicing events as putative mechanisms by which TBI impacts gene network programming and disease predisposition.

To date, perturbations in gene network regulation has also been recognized as a key component of the pathogenesis of neurological disorders ([@bb0185], [@bb0350]). We identified the impact of TBI on the organization of select networks of genes under regulatory control of key driver genes, which may be responsible for the cascade of cellular events involved in the TBI pathology. We found that TBI affects hippocampal and leukocyte gene networks orchestrated by key driver genes associated with the extracellular matrix (e.g., *Fmod*, *Dcn*, *Pcolce*, collagens), transcription factors (e.g., *Tcf7l2*, *Cebpd*), and other functions discussed below (e.g., *Anxa2*, *Ogn*). These master genes are located at the center of gene subnetworks surrounded by TBI signature genes, and are likely key regulatory points of these networks. The extracellular matrix genes *Fmod* and *Pcolce* have been recently experimentally validated as key regulators of cognitive and metabolic functions ([@bb0165]). *Tcf7l2* and *Cebpd* are key transcription factors involved in metabolic processes, diabetes and fat differentiation. The key driver *Anxa2* (annexin A2) has been associated with brain tumor formation ([@bb0345]) and the long-term neurological outcomes of focal embolic stroke ([@bb0305]). In turn, the fact that *Ogn* (osteoglycin) is reduced in the amygdala of animals exposed to stress ([@bb0085]), suggests that this gene can be an important link between TBI and psychiatric-like disorders such as anxiety and depression ([@bb0155]). The fact that TBI-affected genes are tightly connected through key drivers in gene regulatory networks constructed from completely independent studies supports their functional relatedness and their synchronized actions. The identification of key regulatory genes of the entire network spectrum affected by TBI provides a framework for understanding the integrated actions of multiple pathways on the TBI pathology, and offers plausible key interventional targets ([@bb0090], [@bb0330], [@bb0225]).

Although an increasing body of information indicates that TBI is a risk factor for a range of neurological disorders such as CTE, PTSD, AD ([@bb0115], [@bb0200]), mechanisms involved remain elusive. In our rodent model, we found that the signature genes *Cldn4*, *Cldn5*, *Klhdc8a*, *Lrg1*, and *Lrrc10b* are correlated with the latency time in the Barnes maze. Claudins 4 and 5 belong to a family of genes whose protein products are components of tight junctions and regulate permeability of molecules to the intercellular space. Claudin-5 is a tight junction protein that connects [endothelial cells](http://topics.sciencedirect.com/topics/page/Endothelium){#ir0040}, and is considered important for maintaining permeability of molecules within the extracellular space ([@bb0050]). Therefore, it is possible that genes like Claudins could play a role in the regulation of the BBB, which is a prevalent aspect in the TBI pathology. In turn, the claudin gene *CLDN1* has been associated with working memory in human GWAS ([Table 1](#t0005){ref-type="table"}). The actions of *klhdc8a*, *Lrrc10b*, and *Lrg1* in the brain are poorly understood. However, it has been described that the expression of *klhdc8a* is elevated in human glioblastomas ([@bb0175]), and that *Lrg1* is associated with regulation of stress ([@bb0245]) and recollection of contextual fear memories ([@bb0010]). Although none of these genes have been studied in the context of TBI, some of their known functions overlap with physiological manifestations of the TBI pathology. By integrating our rodent findings with human GWAS, we found significant overlap between the rodent TBI genes and candidate genes in human GWAS for several neurodegenerative diseases such as AD, cognitive disorders, PTSD and other neuropsychiatric disorders. In particular, we found 16 hippocampal genes including APOE, which are known to provide genetic predisposition to AD ([@bb0130]), and 9 leukocyte genes that overlapped with AD genes. Additionally, four hippocampal genes and one leukocyte gene have known association with human PTSD. Further, we found 14 hippocampal and 5 leukocyte genes are associated with major depressive disorders in humans. These findings provide important genomic leads to elucidate how the TBI pathology can escalate to neurological/psychiatric disorders, and suggest specific interventional targets.

Our system biology approach was key to reveal a genome-scale link between central and peripheral gene regulation as studied in circulating leukocytes in response to TBI. We chose to examine the genomics of blood leukocytes since they are abundant in the circulation and have been lately found to serve as a source of biomarkers for AD ([@bb0210]) and PD ([@bb0150]). The comparative analysis of genomic signatures revealed homology between leukocytes and hippocampus at gene-, epigenome-, pathway-, and network levels related to vascularity, cell integrity, and immune response. These changes are likely a reflection of the early events post-TBI related to breakdown of the BBB and changes in systemic inflammation in response to injury ([@bb0095]). The 18 common signature genes between the brain and peripheral could point to new leads for leukocyte genomic markers that trace the gene activities in the hippocampus to assess specific functional implications. For example, the share gene *F5*, involved in coagulation process, has been associated with hippocampal atrophy and conduct behavior in human GWAS. In addition, there was a substantial overlap at pathway and network levels between hippocampus and leukocytes, and the great diversity of common pathways harmonizes with the characteristic broad symptomatology of TBI such a blurred vision (rhodopsin-like receptors), headache, nausea, and dizziness ([@bb0115], [@bb0200]). The shared pathways and networks could be used to develop composite genomic biomarkers that aggregate the information from gene expression level, alternative splicing status, and DNA methylation patterns of leukocyte genes within a shared pathway or gene network to accurately predict the pathological state of the brain and link to TBI phenotypes.

In summary, our comprehensive systems investigation shows that concussive injury affects fundamental aspects of gene regulatory mechanisms that maintain brain homeostasis, including epigenomic programming, alternative splicing factors, transcription factors, and novel network regulators. The alterations induced by TBI in all of these gene regulatory components provide molecular support for the emerging clinical reports about the risk posed by TBI on complex human diseases. This information can be used as elements of prognosis as well as a framework to start examining mechanisms by which TBI pathology may contribute to the pathogenesis of select brain disorders. Moreover, our results are unique to identify the effects of TBI on key driver genes that have the capacity to direct main pathways involved in the TBI pathology, and suggest key perturbation points which are plausible interventional targets for TBI. From the biomarker perspective, our results reveal important homologies between central and peripheral gene regulatory mechanisms at transcriptome, epigenome, pathway, and network levels that could serve as basis for novel strategies to identify composite biomarkers of TBI using easily accessible peripheral samples. Lastly, the intersection between numerous genes altered in the rodent model of TBI with human GWAS could account for the risk posed by TBI to neurological and psychiatric disorders in humans. Overall, our results could serve as a platform to investigate the influence of TBI on the etiology of brain disorders.
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Supplementary materialImage 1Supplementary Fig. S1Co-localization of TBI induced differentially expressed genes (DEG) and differential methylation loci (DML) in hippocampus and leukocytes. Horizontal bars indicate rat chromosomes, and pink and green dots are DEG and DML identified by RNA-Seq and RRBS, respectively.Supplementary Fig. S1
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